Common Contracts
13 similar Employment Agreement contracts by Sensei Biotherapeutics, Inc., Invea Therapeutics, Inc, Xometry, Inc., Acumen Pharmaceuticals, Inc.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 12th, 2024 • Invea Therapeutics, Inc • Pharmaceutical preparations • Illinois
This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Shunichiro Okada (“Executive”) and Invea Therapeutics, Inc. (the “Company”), effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Transaction”) (such date, the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 12th, 2024 • Invea Therapeutics, Inc • Pharmaceutical preparations • Maryland
This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Salvatore Alesci (“Executive”) and Invea Therapeutics, Inc. (the “Company”), effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Transaction”) (such date, the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 12th, 2024 • Invea Therapeutics, Inc • Pharmaceutical preparations • Connecticut
This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Krishnan Nandabalan (“Executive”) and Invea Therapeutics, Inc. (the “Company”), effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Transaction”) (such date, the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 28th, 2022 • Acumen Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Virginia
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective January 1, 2022 (the “Effective Date”), by and between Daniel J. O’Connell (the “Executive”) and Acumen Pharmaceuticals, Inc. (the “Company”) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 28th, 2022 • Acumen Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Virginia
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective January 1, 2022 (the “Effective Date”), by and between Wm. Matthew Zuga (the “Executive”) and Acumen Pharmaceuticals, Inc. (the “Company”) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates, including that certain Consulting Agreement between the Company and Executive dated August 16, 2019, that certain Employment Agreement between the Company and Executive dated January 1, 2021, that certain Letter Agreement between the Company and Executive dated March 11, 2021 and that certain Employment Agreement the Company and Executive dated May 15, 2021.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • June 25th, 2021 • Xometry, Inc. • Services-business services, nec • Maryland
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Effective Date”), by and between Xometry, Inc. (the “Company”) and James Rallo (“Executive”). This Agreement amends, restates, and supersedes in its entirety the Executive Employment Agreement between the Company and Executive that was effective April 13, 2020 (the “Prior Agreement”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • June 25th, 2021 • Xometry, Inc. • Services-business services, nec • Maryland
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Effective Date”), by and between Xometry, Inc. (the “Company”) and Peter Goguen (“Executive”). This Agreement amends, restates, and supersedes in its entirety the Offer Letter Agreement between the Company and Executive that was effective February 26, 2018 (the “Prior Agreement”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • June 25th, 2021 • Xometry, Inc. • Services-business services, nec • Maryland
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Effective Date”), by and between Xometry, Inc. (the “Company”) and Randolph Altschuler (“Executive”). This Agreement amends, restates, and supersedes in its entirety any agreement between the Company and Executive that existed with regard to the employment terms detailed below.
FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 3rd, 2021 • Sensei Biotherapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of April 28, 2021 (the “Effective Date”), by and between Sensei Biotherapeutics, Inc. (the “Company”) and Erin Colgan (the “Executive”). This Agreement amends, restates, and supersedes in its entirety the Offer Letter between the Company and Executive that was dated June 10, 2020 (the “Prior Agreement”).
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 1st, 2021 • Sensei Biotherapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Effective Date”), by and between Sensei Biotherapeutics, Inc. (the “Company”) and Robert Pierce, M.D. (the “Executive”). This Agreement amends, restates, and supersedes in its entirety the Amended and Restated Employment Agreement between the Company and the Executive (the “Prior Agreement”).
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 1st, 2021 • Sensei Biotherapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Effective Date”), by and between Sensei Biotherapeutics, Inc. (the “Company”) and Marie-Louise Fjallskog, MD, PhD (the “Executive”). This Agreement amends, restates, and supersedes in its entirety the Amended and Restated Employment Agreement between the Company and the Executive that was effective December 4, 2020 (the “Prior Agreement”).
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 1st, 2021 • Sensei Biotherapeutics, Inc. • Pharmaceutical preparations • California
This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Effective Date”), by and between Sensei Biotherapeutics, Inc. (the “Company”) and Anupama Hoey (the “Executive”). This Agreement amends, restates, and supersedes in its entirety the Amended and Restated Employment Agreement between the Company and the Executive (the “Prior Agreement”).
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 1st, 2021 • Sensei Biotherapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Effective Date”), by and between Sensei Biotherapeutics, Inc. (the “Company”) and John Celebi (the “Executive”). This Agreement amends, restates, and supersedes in its entirety the Amended and Restated Employment Agreement between the Company and the Executive that was effective January 1, 2021 (the “Prior Agreement”).
